Compare Bristol-Myers Squibb Co (BMY) vs EHang Holdings Ltd - ADR (EH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs EHang Holdings Ltd - ADR — how do they compare? Bristol-Myers Squibb Co trades at $59.02 (market cap $116.30B), while EHang Holdings Ltd - ADR trades at $5.56 (market cap $413.36M). The key difference: Bristol-Myers Squibb Co is far larger — about 281.4× EHang Holdings Ltd - ADR's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals.
| BMY | EH | |
|---|---|---|
Market Cap | $116.30B | $413.36M |
Sector | Health | Industrials |
52-Week High | $62.37 | $19.99 |
52-Week Low | $42.60 | $5.41 |
Enterprise Value | $152.24B | $353.02M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
EHang Holdings (EH) trades at $5.41, down 3.22% on the day, reflecting ongoing volatility in the advanced air mobility sector. The stock shows a bearish technical trend with oversold RSI signals, while fundamentals reveal persistent losses with a net margin of -77.56% in 2025 despite a gross margin of 61.53%. Recent Q1 2026 earnings beat expectations but highlighted a sharp quarterly revenue drop, underscoring execution challenges amid expansion efforts.
The outlook remains high-risk with mixed analyst sentiment; a $6.97 consensus target suggests modest upside, but deep losses and cash burn necessitate careful monitoring of commercialization progress. Key risks include operational scalability, regulatory hurdles, and intense competition in the emerging eVTOL market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →
